EGFR and non-small cell lung carcinoma: The development of EGFR-TKIs [32] has raised hopes of improved prognosis in patients with NSCLC; however, the effectiveness of EGFR-TKI monotherapy is challenged by the acquisition of resistance to EGFR-TKIs due to intrinsic genetic factors or extrinsic long-term chemotherapy.